MASCT by Hengrui Yuanzheng Biotechnology for Solid Tumor: Likelihood of Approval

MASCT is under clinical development by Hengrui Yuanzheng Biotechnology and currently in Phase I for Solid Tumor.

Q&A: Trans adults face ‘shocking’ risk of cirrhosis, especially alcohol-driven

People under 45 have been driving an increase in liver-related deaths, especially those caused by alcohol. But a sliver of that young adult population is

July 22, 2024

Boulder Care Secures $35M to Expand Telehealth Addiction Treatment for Underserved Communities

What You Should Know: – Boulder Care, a leading provider of high-quality addiction treatment, announced today the successful closing of an oversubscribed $35M Series C

May 24, 2024

The biotech scorecard for the third quarter: 19 stock-moving events to watch

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Late last month, Alnylam Pharmaceuticals reported positive, top-line results

July 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.